Can't say I understand the mode of action of their drug though.
Prof. Cohen from the Weizmann Institute, who developed DiaPep277 believes the peptide activates a subgroup of T-cells which down-regulate the pathogenic T-cells that cause type 1 diabetes. This regulation change the cytokine profile secreted by the pathogenic T-cells: pro-inflammatory cytokines, which are lethal to the insulin-producing beta-cells, are replaced by cytokines that can inhibit inflammatory reactions and this change shuts off the immune attack on beta-cells.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.